What changed for Tuberculosis
A plain English summary of what recently moved in the public data Voxsanity tracks for Tuberculosis. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 148 to 149 (+1)
- Trials on record 1,539 to 1,542 (+3)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Tuberculosis yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 101 trials tracked for Tuberculosis that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05630872 · results posted 20 July 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 30 adults living with HIV who had also been newly diagnosed with drug-sensitive tuberculosis (TB) and were not yet on HIV treatment. The trial was measuring how a HIV medication called dolutegravir (DTG) behaves in the body when taken alongside a TB treatment regimen that includes a drug called rifapentine (plus isoniazid, pyrazinamide, and ethambutol). Twenty-eight of the 30 participants completed the study, and two did not complete it. The trial was focused on pharmacokinetics — that is, tracking how the medication...
-
NCT03266003 · results posted 2 July 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT03266003) enrolled 211 people in total — 109 in one group and 102 in the other. It was a crossover study, meaning each person tried both methods of directly observed therapy (DOT) for tuberculosis (TB) medication: in-person DOT (ipDOT), where a staff member watches the person take their medication face-to-face, and electronic DOT (eDOT), where the person records a video of themselves taking their medication for staff to review. The trial's main goal was to measure how many medication doses were actually observed by staff u...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05413551 · results posted 15 June 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 78 people in total, split into three groups based on how quickly their bodies process a tuberculosis antibiotic called isoniazid: 10 "rapid acetylators," 34 "intermediate acetylators," and 34 "slow acetylators." These labels describe a genetic difference in how fast a person breaks down the drug. The trial was measuring how isoniazid moves through the body — specifically how much of the drug is present in the blood over time, how quickly the body clears it, and what peak levels are reached. By the end of the study, 9...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05327803 · results posted 10 June 2026
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called epetraborole, given alongside an existing background treatment regimen (referred to as OBR), compared with a placebo (a dummy treatment) also given with OBR. The trial ran in two stages — Phase 2 and Phase 3. In Phase 2, 39 people were assigned to epetraborole plus OBR and 41 to placebo plus OBR, with 35 and 34 respectively completing that phase. In Phase 3, 66 people started in the epetraborole plus OBR group and 31 in the placebo plus OBR group, with 52 and 22 completing it. The trial was measurin...
-
NCT00164281 · results posted 27 May 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,995 participants in total — 1,006 in the continuous isoniazid group and 989 in the limited (placebo) isoniazid group. The trial was measuring whether taking isoniazid (an antibiotic used against tuberculosis) continuously over time made a difference compared to a shorter, limited course, in people followed up over 36 months. The main thing researchers tracked was how many participants developed tuberculosis (TB). They also tracked how many participants died from any cause, and a combined count of those who either de...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05007821 · results posted 1 May 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05007821) enrolled 138 people in total — 69 in Arm A and 69 in Arm B. The trial was looking at treatments for tuberculosis (TB), and it measured two main things: how quickly participants' sputum (mucus) samples stopped showing signs of TB bacteria over 26 weeks, and how many participants permanently stopped taking at least one of their TB medicines due to side effects, intolerance, or death. A secondary focus was the proportion of participants whose sputum samples had cleared of TB bacteria at specific points in time (week...
-
NCT03512249 · results posted 24 February 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 831 adults — 415 in the H56:IC31 vaccine group and 416 in the placebo group. The trial was testing a tuberculosis (TB) vaccine called H56:IC31 in people who had already been treated for TB, to see whether it could reduce the chances of TB coming back, either as a return of the same infection (relapse) or a new infection with a different strain (reinfection). Participants were HIV-negative and had recently completed most of their TB treatment. By the end of the trial, 358 people in the vaccine group and 384 in the plac...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05027958 · results posted 6 November 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 17 healthy volunteers in total — 7 people who had latent tuberculosis infection (LTBI, meaning the TB bacteria are present in the body but not causing active illness) and 10 people who did not have LTBI. The trial was measuring how the immune system responds in the lungs when a small amount of a TB-related protein (called tuberculin PPD) is placed directly into the airway. Specifically, it looked at a type of immune cell called CD4 T cells, and also used a special full-body scan (PET-CT) to look at activity levels in...
-
NCT04311502 · results posted 27 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04311502) enrolled 104 people across three groups: 58 in the experimental treatment arm, 31 in the standard-of-care arm, and 15 in a smaller subgroup focused on how the body processes the drug (called a pharmacokinetics, or "PK," subgroup). The trial was measuring two main things: how quickly participants' sputum (mucus coughed up from the lungs) stopped showing signs of tuberculosis (TB) bacteria in laboratory tests, and how many participants experienced serious unwanted health events (called adverse events, graded on a s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04556981 · results posted 17 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04556981) involved 402 participants in total — 202 received the M72/AS01E candidate tuberculosis vaccine and 200 received a placebo (an inactive injection). The trial was primarily measuring the number of participants who experienced certain health events after each of their two injections, including both "solicited" events (symptoms participants were specifically asked to record in a diary, such as pain at the injection site, fever, headache, fatigue, and muscle aches) and "unsolicited" events (any other health events not...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06041919 · results posted 15 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT06041919) enrolled 20 participants in total — 15 in the active treatment group (Group 1) and 5 in a control group (Group 2). Groups 3, 4, and 5 were listed but had no participants recorded. Of those who started, 14 active-group participants and 4 control-group participants completed the study. The trial was measuring something called "Early Bactericidal Activity" — essentially, how quickly the number of live tuberculosis bacteria in participants' sputum (mucus coughed up from the lungs) changed over time after receiving in...
-
NCT04703075 · results posted 19 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04703075) enrolled 500 adults and adolescents who did not have HIV but were considered at increased risk of tuberculosis (TB). Participants were split into two groups: 249 people received a treatment referred to as "1HP" (Arm A) and 251 received a treatment referred to as "3HP" (Arm B). The trial was measuring two main things — how many people in each group completed their treatment as directed (taking more than 90% of their doses), and how many experienced notable side effects or stopped treatment early because of side ef...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04152161 · results posted 19 June 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 919 people in the BCG vaccine group and 917 people in the placebo (dummy injection) group — a total of 1,836 participants. The trial was measuring whether receiving the BCG vaccine (a well-known tuberculosis vaccine) affected the likelihood of people testing positive for tuberculosis infection over time. This was tracked using a blood test called QuantiFERON-TB Gold Plus (QFT), which detects signs that the immune system has been exposed to tuberculosis bacteria. The researchers were specifically looking for "sustained...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04221789 · results posted 21 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04221789) involved 555 people being treated for tuberculosis (TB). Participants were split into two groups: 277 people used something called a "TB Treatment Assistant" (a digital or app-based tool to support their treatment), and 278 people were in a control group, meaning they received the usual care without this tool. The trial was measuring how many people successfully completed their six-month TB treatment course, and how many stopped taking their treatment early. The reported data shows that, when it came to completi...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05640648 · results posted 30 March 2025
According to the results reported on ClinicalTrials.gov, this trial looked at two different approaches to "contact investigation" for tuberculosis (TB) — a process where health workers track down people who may have been exposed to someone with TB and arrange for them to be tested. The standard approach was compared with a "user-centred" approach, which was designed with input from the people using it. The trial ran across 12 health facilities and used a crossover design, meaning each facility took turns using both approaches across different time periods. Participants included both "index" in...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02906007 · results posted 21 March 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 54 children with HIV across three age groups: 18 children aged 6 to under 18 years (Cohort 1), 18 children aged 2 to under 6 years (Cohort 2), and 18 infants and toddlers aged under 2 years (Cohort 3). The trial was measuring a range of safety-related events — including serious unwanted health events, deaths, heart rhythm problems, and whether any child had to stop the study drug because of a drug-related event — over the course of the study. The reported data shows that when it came to serious unwanted health events...
-
NCT03544476 · results posted 10 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03544476) looked at whether a mobile phone app designed to support tuberculosis (TB) treatment could help people stay on track with their medication. A total of 42 people took part — 21 who used the mobile phone TB treatment support app, and 21 who received usual care. Everyone who started the trial also completed it, with no drop-outs recorded in either group. The reported data shows that, for the main outcome — the number of people who achieved "treatment success" (meaning they either completed their course of TB treatm...
-
NCT05282173 · results posted 6 March 2025
According to the results reported on ClinicalTrials.gov, this trial involved 82 community health workers (CHWs) across three groups, with 73 completing the study. The trial was testing a training programme called "Siyakhana," designed for community health workers. It looked at whether the training was practical to deliver and acceptable to those who took part, and also measured whether the training was associated with any changes in how much stigma (negative attitudes or desire to avoid) the health workers held towards people with substance use issues or depression. The reported data shows th...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03044158 · results posted 18 February 2025
According to the results reported on ClinicalTrials.gov, this trial involved 10,644 people in total — 5,098 in the control group and 5,546 in the intervention group. Every person who started the trial was recorded as completing it, with no drop-outs reported in either group. The trial was measuring outcomes related to tuberculosis (TB) diagnosis and treatment, comparing two groups to see whether differences could be observed in how quickly and how often people were diagnosed and started on treatment for TB. The reported data shows that for the main (primary) outcome — the number of people tre...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04520113 · results posted 10 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04520113) was conducted across two sites in South Africa — Limpopo and Soshanguve — and involved a total of 10,579 participants across four groups. The study was looking at different ways of tracing the close contacts of people newly diagnosed with tuberculosis (TB). The four approaches tested were: standard contact tracing in Limpopo (4,368 participants), a "holiday tracing" approach where visits were timed around public holidays (1,952 participants), an "evening and weekend tracing" approach (1,320 participants), and sta...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03492216 · results posted 13 January 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 680 people across four groups. All participants were people living with HIV who were also taking isoniazid (a medicine used to prevent tuberculosis). The trial was testing whether offering financial rewards — called incentives — could encourage people to drink alcohol at lower-risk levels and to take their isoniazid medicine more consistently. Participants were randomly placed into one of four groups: a control group (no incentives), a group offered incentives based on urine alcohol tests, a group offered incentives b...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02619994 · results posted 3 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02619994) enrolled 214 people in total — 106 in the control arm and 108 in the experimental arm. The trial was comparing two different treatment approaches, measuring things like how many participants achieved "treatment success," how quickly their sputum (mucus coughed up from the lungs) cleared of bacteria, and whether bacteria came back after treatment ended. Not everyone finished the trial: 89 people in the control arm and 79 in the experimental arm completed it. The reported data shows that for the main outcome — tre...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04874948 · results posted 5 December 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 4 healthy adult male volunteers, and all 4 completed the study. The trial was investigating a drug called BTZ-043, which is being researched in relation to tuberculosis. Participants received a single oral dose of 500 mg of BTZ-043 that contained a small amount of a radioactive "tracer" version of the drug. This tracer allowed researchers to track where the drug and its breakdown products (called metabolites) travelled in the body, how quickly they were absorbed into the bloodstream, and how they were eventually remov...
-
NCT04550832 · results posted 28 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04550832) enrolled 76 people across five groups to study different doses of a drug referred to as DZD (dazanamide) for tuberculosis. The groups were: a placebo group receiving no active drug (15 people), and four groups receiving different doses — 400 mg once daily (15 people), 800 mg once daily (15 people), 1,200 mg once daily (16 people), and 800 mg twice daily (15 people). The trial was primarily measuring how often participants experienced side effects, and also looking at how the drug moved through the body and whethe...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04179500 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 26 male participants who received a treatment regimen referred to as BPaMZ — a combination of tuberculosis medicines. The trial was measuring how the treatment affected sperm count over time, as well as tracking certain hormone levels in the blood. Of the 26 who started the treatment phase, 22 completed it, and 18 completed the full follow-up period. The reported data shows that the main thing being measured was the change in total sperm count (the number of sperm cells in a single ejaculate, measured in millions) fr...
-
NCT05122624 · results posted 23 July 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT05122624) involved 3,332 people across two groups — 1,826 in the "Score Intervention Arm" (where a tool called PredicTB was used to guide decisions about starting tuberculosis treatment on the same day) and 1,506 in the "Control Arm" (where standard care was provided). All participants who started the trial completed it. The trial was primarily measuring whether using the PredicTB scoring tool changed how quickly people with confirmed tuberculosis (TB) began treatment, specifically whether they started within 7 days. The...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04188041 · results posted 19 July 2024
According to the results reported on ClinicalTrials.gov, this trial looked at a programme designed to improve how healthcare providers identify and manage latent tuberculosis infection (LTBI — where someone carries the TB bacteria but is not yet ill). The study had three separate parts: one involving 25 people who took part in interviews about the topic; one involving 8 healthcare providers who joined an online learning programme called ECHO (a type of regular group learning session); and one involving a review of 51 patient medical records. The focus of the ECHO part — which is where most of...
-
NCT03421743 · results posted 3 July 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03421743) enrolled 32 people in total across two groups. Fourteen participants received inhaled molgramostim (a type of inhaled medication) combined with standard antimycobacterial antibiotics, while 18 received inhaled molgramostim on its own. The trial was primarily measuring whether a bacterial infection in the lungs — caused by non-tuberculous mycobacteria (NTM), a type of germ found in the environment — could be cleared from participants' sputum (mucus coughed up from the lungs). Eleven people in the combination group...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04176250 · results posted 11 April 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04176250) enrolled 93 people across six groups to study a new experimental drug called TBA-7371 for tuberculosis (TB). Four groups received different doses and schedules of TBA-7371, one group received it three times a day at 100 mg, and one comparison group received a standard four-drug TB treatment (known as HRZE). The trial ran for 14 days and was primarily measuring how quickly the amount of TB bacteria in participants' sputum (phlegm) changed over that period, as well as tracking serious unwanted medical events. The...
-
NCT05124665 · results posted 14 February 2024
According to the results reported on ClinicalTrials.gov, this trial involved 612 participants in total across two groups in Uganda. The Social Support group had 364 participants (79 "index patients" — people already known to have HIV or TB — and 285 of their household contacts). The Standard of Care group had 248 participants (61 index patients and 187 household contacts). The trial was measuring whether a social support-based approach could increase the number of household contacts who agreed to be tested for HIV, and whether it was associated with changes in how much stigma people felt aroun...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 101 reported results for Tuberculosis
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, tuberculosis currently attracts a very large amount of public research funding from the United States, and that investment has remained broadly steady from year to year. This pattern suggests that tuberculosis is an established and ongoing research priority at the international level, rather than a newly emerging one. For patients, steady and substantial funding gene...
See the full Tuberculosis page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.